肺孢子菌肺炎的临床研究进展  

Progress of clinical research on Pneumocystis carinii pneumonia

作　　者：李君 牟向东 李海潮[2] 刘新民[3] Li Jun;Mu Xiangdong;Li Haichao;Liu Xinmin(Department of Respiratory and Critical Care Medicine,Beijing Tsinghua Changgung Hospital,Beijing 102218,China;Department of Respiratory and Critical Care Medicine,Peking University First Hospital,Beijing 100034,China;Department of Geriatric Medicine,Peking University First Hospital,Beijing 100034,China)

机构地区：[1]北京清华长庚医院呼吸与危重症医学科,北京102218 [2]北京大学第一医院呼吸与危重症医学科,北京100034 [3]北京大学第一医院老年病内科,北京100034

出　　处：《国际呼吸杂志》2024年第10期1229-1235,共7页International Journal of Respiration

基　　金：北京市重大疫情防治临床重点专科建设项目(XKB2022B1002)。

摘　　要：肺孢子菌肺炎(PCP)是一种严重的机会性感染疾病,随着诊疗技术的不断进步,在人类免疫缺陷病毒(HIV)感染者中PCP已得到一定的控制,但PCP却逐渐成为肿瘤放化疗、免疫治疗、器官移植术后抗排异治疗,以及自身免疫性疾病治疗等所致免疫功能低下或免疫功能受损人群越来越常见的死亡原因。全球范围内PCP的研究热点正在从HIV-PCP向非HIV-PCP转变。本文将分析研究趋势的改变情况,并重点关注HIV-PCP与非HIV-PCP发病机制、临床表现的比较,以及非HIV-PCP危险因素的识别、诊治、预防进展,并探讨PCP研究的新方向。Pneumocystis carinii pneumonia(PCP)is a severe opportunistic infection disease.With the emerging diagnosis and treatment technologies,PCP has been controlled in human immunodeficiency virus(HIV)infected patients.PCP has gradually become a common cause of death in people with low or impaired immune function caused by tumor radiotherapy,chemotherapy,immunotherapy,anti-rejection treatment after organ transplantation,and treatment of autoimmune diseases.The research focus of PCP globally is shifting from HIV-PCP to non-HIV-PCP.This article analyzed the changes in research trends and focused on the comparative study of the pathogenesis,clinical manifestations of HIV-PCP and non-HIV-PCP,the identification of risk factors,diagnosis,and prevention for non-HIV-PCP,and the exploration of new directions in PCP research.

关 键 词：肺炎 肺囊虫性 HIV感染 CD4阳性T淋巴细胞 CD8阳性T淋巴细胞 危险因素 

分 类 号：R519[医药卫生—内科学]